22 citations
,
September 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” This review highlights the possible role of T regulatory cells in the immune-related mechanisms of alopecia areata but reports no new clinical findings.
30 citations
,
September 2020 in “Journal of Patient-Reported Outcomes” This study found that alopecia areata significantly impacts emotional and psychological well-being, relationships, and lifestyles, highlighting the need for increased awareness and effective treatments.
4 citations
,
January 2020 in “PubMed” This source reports that JAK inhibitors, such as ruxolitinib, baricitinib, and tofacitinib, have led to hair regrowth in alopecia areata patients and animal models, but their long-term safety and effectiveness remain uncertain, with ongoing trials to further investigate these factors.
29 citations
,
December 2019 in “Expert review of clinical pharmacology” This review discusses the evidence supporting Janus kinase inhibitors for alopecia areata and highlights ongoing optimism as phase 3 trials begin, with no new clinical results reported.
8 citations
,
October 2019 in “Immunological investigations” This study suggests that the rs2075876 variant in the AIRE gene may significantly increase susceptibility to alopecia areata in the examined male population.
46 citations
,
August 2019 in “Journal of the European Academy of Dermatology and Venereology” This study found that patients with alopecia areata reported worse quality of life and higher anxiety and depression levels compared to those with androgenetic alopecia and healthy controls.
44 citations
,
April 2019 in “Journal of the American Academy of Dermatology” This study observed that cyclosporine showed a trend toward improving alopecia areata symptoms compared to placebo, but the difference was not statistically significant.
66 citations
,
December 2018 in “Dermatology” This study found that oral JAK inhibitors, ruxolitinib and tofacitinib, are effective and well-tolerated for treating severe alopecia areata, with a similar degree of hair regrowth and relapse rates, but ruxolitinib induced faster initial hair regrowth.
29 citations
,
November 2018 in “Journal of The European Academy of Dermatology and Venereology” This study found that anxiety-related traits significantly predict the impact of hair loss on quality of life across different alopecia types, with variations observed based on gender.
8 citations
,
October 2018 in “Journal of Investigative Dermatology” This study observed that alopecia areata patients experience significant psychosocial issues, with a high prevalence of anxiety, depression, and impaired quality of life across symptoms, functioning, and emotions.
23 citations
,
August 2018 in “Anais Brasileiros De Dermatologia” This study found that patients with androgenetic alopecia reported more impact on their quality of life in terms of emotions, functioning, and symptoms than those with alopecia areata.
13 citations
,
January 2018 in “Annals of Dermatology” Alopecia areata and androgenetic alopecia affect quality of life similarly.
3 citations
,
November 2017 in “PubMed” This study found that individuals with alopecia areata experience variations in cortisol and insulin levels and adaptive mechanism pressures, which may serve as potential therapeutic targets.
17 citations
,
July 2017 in “International Journal of Behavioral Medicine” This study validated the Egyptian Arabic version of the Skindex-16 and found that skin conditions significantly impacted patients' quality of life, particularly in the emotional domain.
32 citations
,
January 2017 in “Patient Preference and Adherence” This study found that both alopecia areata and androgenetic alopecia moderately reduced the quality of life for Chinese patients, especially in younger individuals and those experiencing hair loss for over a year.
17 citations
,
May 2016 in “Journal of Psychosomatic Research” This study observed that in patients with androgenetic alopecia, illness perception was linked to higher psychological distress and lower quality of life compared to those with alopecia areata.
128 citations
,
February 2016 in “British Journal of Dermatology” This study found that patients with alopecia areata experience significant impairments in health-related quality of life, notably affecting mental health, according to various quality of life assessment tools.
25 citations
,
December 2015 in “Journal of the European Academy of Dermatology and Venereology” This study found that alopecia areata negatively affects patients' quality of life, though less severely than psoriasis, atopic dermatitis, and onychomycosis.
144 citations
,
July 2015 in “Clinical, Cosmetic and Investigational Dermatology” This review reports that alopecia areata affects about 2% of people globally and is linked with psychiatric and medical comorbidities, highlighting its significant disease burden.
45 citations
,
January 2013 in “Dermatology Research and Practice” This study found that patients with alopecia areata experience significantly poorer quality of life compared to the general population, affecting mental health, social functioning, and overall health outcomes.
9 citations
,
December 2012 in “The Journal of Dermatology” Wearing wigs or hairpieces improves self-esteem, adaptability, and competence in women with alopecia areata.
101 citations
,
January 2012 in “Annals of Dermatology” In this study, researchers found that androgenetic alopecia significantly harms quality of life, particularly in younger patients, those with more severe or long-term alopecia, and those who have sought non-medical hair care.
86 citations
,
May 2011 in “Journal of The American Academy of Dermatology” This study found that patients with alopecia perceive their hair loss as more severe than dermatologists do, and their own ratings of hair loss severity better reflect their quality of life impacts.
44 citations
,
August 2010 in “Journal of Investigative Dermatology” Alopecia areata seriously lowers quality of life, especially affecting self-image, mental health, and social life.
